| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a917e0abc9c98019b6ad34a548f795f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf0f68bc9b66c444a1b7b970ce248f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c469271060efc416fa7a8ba6ea7e8951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7b7aea0e436c4b74699b8c6b83ed529
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b38b28f67efda8f62c863245e866cfd2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2006-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b1623724fd9f4fc4719433810ca87b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f664160979e593fd125f37d225ccd0dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_381cce0f8087c795a46f2ec932c40df7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6bcc90eaecfb86bfb88d090a50094d0 |
| publicationDate |
2007-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006125077-A3 |
| titleOfInvention |
Non-natural chemokine receptor ligands and methods of use thereof |
| abstract |
The present invention provides non-natural CXCR3 ligands comprising the N-loop region of the iTAC and polynucleotide encoding such non-natural CXCR3 ligands. The invention additionally provides methods of treating fĂbrotic disorders, angiogenic disorders, and cancer. The methods generally involve administering to an individual in need thereof an effective amount of a non-natural CXCR3 ligand of the invention. |
| priorityDate |
2005-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |